Bill Summary for H 243 (2017-2018)
Printer-friendly: Click to view
Summary date:
Bill Information:
| View NCGA Bill Details | 2017-2018 Session |
AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS; REQUIRING SUPERVISING PHYSICIANS TO PERSONALLY CONSULT WITH PHYSICIAN ASSISTANTS AND NURSE PRACTITIONERS WHO PRESCRIBE CERTAIN SCHEDULE II OR III CONTROLLED SUBSTANCES FOR LONG-TERM USE; REQUIRING ELECTRONIC PRESCRIBING OF CERTAIN SCHEDULE II AND III CONTROLLED SUBSTANCES; ESTABLISHING MAXIMUM LIMITS FOR INITIAL PRESCRIPTIONS OF SCHEDULE II AND III CONTROLLED SUBSTANCES; REQUIRING HOSPICE AND PALLIATIVE CARE PROVIDERS TO PROVIDE EDUCATION REGARDING PROPER DISPOSAL OF CERTAIN UNUSED CONTROLLED SUBSTANCES; CLARIFYING ALLOWABLE FUNDS FOR SYRINGE EXCHANGE PROGRAMS; REQUIRING VETERINARIAN PARTICIPATION IN THE CONTROLLED SUBSTANCES REPORTING SYSTEM; ESTABLISHING CIVIL PENALTIES FOR PHARMACIES THAT EMPLOY DISPENSERS WHO IMPROPERLY REPORT INFORMATION TO THE CONTROLLED SUBSTANCES REPORTING SYSTEM (CSRS); EXPANDING THE ROLE OF THE DEPARTMENTS OF HEALTH AND HUMAN SERVICES (DHHS) IN USING CSRS DATA TO DETECT AND PREVENT FRAUD AND MISUSE; MANDATING DISPENSER REGISTRATION FOR ACCESS TO THE CSRS; MANDATING DISPENSER AND PRACTITIONER USE OF THE CSRS; REQUIRING DHHS TO REPORT PRACTITIONERS WHO FAIL TO PROPERLY USE THE CSRS; CREATING A SPECIAL REVENUE FUND TO SUPPORT THE CSRS; AND REQUIRING AN ANNUAL REPORT FROM DHHS ON THE CSRS.Intro. by Murphy, Davis, Malone, Horn.
| View: All Summaries for Bill | Tracking: |
Bill summary
House amendments make the following changes to the 2nd edition.
House amendment #1 amends proposed GS 90-87(26a), defining targeted controlled substance to mean any controlled substance included in GS 90-90(1) or (2), or GS 90-91(d) (previous edition also included GS 90-90(3)).
House amendment #2 further amends GS 90-106 by adding a new subsection. Requires that if a prescription is for a targeted controlled substance and therapeutic use of the targeted controlled substance will or is expected to exceed a period of 60 days, the practitioner prescribing the targeted controlled substance must execute a pain management agreement with the patient that includes eleven specified elements, including the agreement date; the patient name and practitioner name; the name of the targeted drug(s), dosage amount, and frequency of administration; refill policy; random drug testing; and policy for agreement termination. Effective January 1, 2018. Makes technical and conforming changes.